Vitamin B12 Injection Frequency and Laboratory Monitoring
Standard Injection Schedule
For patients with confirmed B12 deficiency due to malabsorption (pernicious anemia, ileal resection >20 cm, post-bariatric surgery, atrophic gastritis), the standard maintenance regimen is hydroxocobalamin 1000 µg intramuscularly every 2–3 months for life after initial loading doses. 1
Initial Loading Phase
With neurological symptoms (paresthesias, cognitive difficulties, gait disturbance, glossitis): Give hydroxocobalamin 1 mg IM on alternate days until neurological improvement plateaus (typically weeks to months), then transition to maintenance. 1, 2
Without neurological symptoms: Give hydroxocobalamin 1 mg IM three times weekly for 2 weeks, then proceed to maintenance. 1, 2
Maintenance Dosing
Standard regimen: Hydroxocobalamin 1000 µg IM every 2–3 months for life. 1, 3
Monthly alternative: Some patients require 1000 µg IM monthly to meet metabolic requirements, particularly those with persistent symptoms, post-bariatric surgery, or extensive ileal disease. 1, 4 Up to 50% of patients may need more frequent dosing (ranging from twice weekly to every 2–4 weeks) to remain symptom-free. 5
Post-bariatric surgery: Hydroxocobalamin 1000 µg IM every 3 months indefinitely, or oral B12 1000–2000 µg daily as an alternative. 1, 6
Laboratory Monitoring Schedule
The recommended monitoring schedule is: 3 months, 6 months, 12 months after starting treatment, then annually thereafter once levels stabilize. 1
What to Measure at Each Visit
- Serum B12 as the primary marker 1
- Complete blood count to assess resolution of megaloblastic anemia 1
- Methylmalonic acid (MMA) if B12 levels remain borderline (180–350 pg/mL) or symptoms persist; target <271 nmol/L 7, 1
- Homocysteine as an additional functional marker; target <10 µmol/L for optimal cardiovascular outcomes 7, 1
- Concurrent micronutrients (iron studies, folate, vitamin D, thiamine) at the same intervals, as deficiencies commonly coexist 1
Timing of Blood Draw
Draw blood directly before the next scheduled injection (at the end of the dosing interval) to identify potential under-dosing; this trough level provides the most clinically relevant information. 1
Special Population Monitoring
Post-bariatric surgery patients planning pregnancy: Check B12 levels every 3 months throughout pregnancy due to permanent malabsorption and higher requirements. 1, 2
High-risk patients (ileal Crohn's disease >30–60 cm involvement, chronic PPI/metformin use, age >75 years): Screen annually even without documented deficiency. 7, 1
Critical Precautions
Never administer folic acid before correcting B12 deficiency—folic acid can mask megaloblastic anemia while allowing irreversible subacute combined degeneration of the spinal cord to progress. 1, 8 Only add folic acid 5 mg daily after B12 repletion if folate deficiency is documented. 1
Do not stop monitoring after one normal result—patients with malabsorption require lifelong supplementation and can relapse. 1 Continue annual monitoring indefinitely. 1
Do not "titrate" injection frequency based on serum B12 or MMA levels—adjust dosing based on symptom control rather than laboratory values. 5 If neurological symptoms recur despite "normal" labs, increase injection frequency. 1, 2
Formulation Selection
Hydroxocobalamin is the preferred injectable form due to superior tissue retention and established dosing protocols. 1
Avoid cyanocobalamin in patients with renal dysfunction (eGFR <50 mL/min)—use hydroxocobalamin or methylcobalamin instead, as cyanocobalamin requires renal clearance of cyanide and is associated with doubled cardiovascular risk (HR 2.0) in diabetic nephropathy. 1, 8